May 11, 2020 / 1:22 PM / 24 days ago

BRIEF-Oyster Point Pharma Reports Q1 2020 Financial Results

May 11 (Reuters) - Oyster Point Pharma Inc:

* OYSTER POINT PHARMA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

* Q1 LOSS PER SHARE $0.77

* OYSTER POINT PHARMA - POSITIVE RESULTS IN ONSET-2 PHASE 3 TRIAL OF OC-01 NASAL SPRAY

* OYSTER POINT PHARMA - ONSET-2 DATA ENABLES NDA SUBMISSION IN 2H 2020

* OYSTER POINT PHARMA - CASH, CASH EQUIVALENTS OF $128.6 MILLION AS OF MARCH 31, 2020

* ONSET-2 PHASE 3 STUDY MET PRESPECIFIED PRIMARY ENDPOINT IN BOTH DOSES TESTED

* ONSET-2 PHASE 3 STUDY MET KEY SECONDARY SYMPTOM ENDPOINTS IN 1.2 MG/ML DOSE GROUP Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below